Zydus Lifesciences’ revenue was largely in-line with our estimates. EBITDA missed our estimates due to lower-than-expected gross profit and higher-than-expected other expenses. However, Adj. PAT was in-line with our estimates as EBITDA miss was offset by lower-than-expected tax expenses.